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OBJECTIVES The study evaluated the role of the autonomic nervous system in atrial fibrillation (AF)
recurrence.
BACKGROUND Early recurrence of AF after cardioversion (CV) is attributed to electrical remodeling. The
possibility that an abnormal autonomic modulation might contribute to this phenomenon has
not yet been adequately tested.
METHODS We analyzed short-term heart rate variability (HRV) in 93 patients with persistent AF and
on chronic amiodarone treatment, after restoration of sinus rhythm by electrical CV.
RESULTS Two weeks later, 25 patients presented with AF. Spectral analysis of HRV revealed that
patients with AF recurrence were characterized by significantly greater low/high (LF/HF)
frequency ratio in comparison to those in sinus rhythm (5.8 6 6.86 vs. 1.1 6 1.7). At
univariable analysis, no clinical parameter differentiated the two groups. Using logistic
regression analysis, LF/HF ratio was significantly associated with AF recurrence, with an
odds ratio of 1.97 (95% confidence interval [CI] 1.33–2.94). By using a cutoff value of $2,
LF/HF ratio presented a sensitivity and a specificity of, respectively, 76% and 90%. AF
recurred in 9% of the patients with LF/HF ratio ,2 compared with 73% of those with an
LF/HF ratio .2. No correlation was observed between LF/HF ratio and late AF recurrences.
CONCLUSIONS These data indicate that signs of increased sympathetic and reduced vagal modulation of sinus
node characterized patients with an early AF recurrence and suggest that an abnormal
autonomic control may contribute to electrical remodeling by facilitating intracellular calcium
overload. (J Am Coll Cardiol 2001;37:157–62) © 2001 by the American College of
Cardiology
Maintenance of sinus rhythm after electrical or pharmaco-
logical cardioversion (CV) of atrial fibrillation (AF) is a
major clinical problem. Available data (1) indicate that, in
most instances, 40% to 60% of patients have recurrence of
AF after CV even in the presence of an appropriate
anti-arrhythmic therapy. It is generally recognized that
patients prone to recurrences have a more severe left
ventricular dysfunction and a larger atrial size, as well as a
longer history of arrhythmia. However, in many cases,
reappearance of AF is almost unavoidable despite control of
factors that may play a pro-arrhythmic role, such as hyper-
tension or congestive heart failure.
More recently, attention has been paid for timing of
recurrences. It was reported (2) that in more than one-third
of cases, AF recurs within two weeks after CV. Thereafter,
the probability of recurrence decreases and becomes more
constant over time. Thus, identification of the factors
involved in this early phase may facilitate an understanding
of this phenomenon and guide a more appropriate anti-
arrhythmic therapy.
Several reports have indicated that duration of AF is
associated with major changes in cardiac electrical properties
that may favor arrhythmia recurrence (1,3). Structural remod-
eling has also been considered as a critical pro-arrhythmic
factor (4,5). Less emphasis has been attributed to a possible
role of the autonomic nervous system. In the past, the term
vagal or sympathetic AF (6) has been used to characterize the
autonomic environment in which AF has been reported to
occur. No attention was instead directed to the possibility that
a specific autonomic pattern could facilitate AF recurrence
after electrical or pharmacological CV.
We therefore used spectral analysis of short-term heart
rate variability (HRV) to evaluate autonomic modulation of
the sinus node after restoration of sinus rhythm in patients
with persistent AF, and we correlated spectral parameters
with the incidence of early and late AF recurrence in
patients under chronic amiodarone treatment.
METHODS
From September 1997 to January 1999, 126 patients with
persistent AF gave informed consent to participate to the
study. After a complete physical examination and two-
dimensional echocardiography, patients were started on
amiodarone (oral load plus 200 mg/daily) and on warfarin if
not already on anticoagulant therapy. In 38 patients, a
transesophageal echocardiographic examination was also
performed.
After four weeks of treatment, all patients were scheduled
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for a 24-h hospital admission to perform electrical CV. In
13 cases spontaneous restoration of sinus rhythm occurred
and patients were excluded. In the remaining ones, electrical
CV was performed in the late morning hours under slight
sedation (propofol 2 mg/kg) by means of DC shock deliv-
ered by commercial defibrillator (Codemaster XL, Hewlett
Packard) with a starting energy of 200 J. In 52 subjects a
second DC shock (360 J) was delivered. Restoration of sinus
rhythm was obtained in 103 of 113 subjects (91%). Control
visits with medical examination and 12-lead electrocardio-
gram (ECG) were scheduled at 12 to 15 days, one, three
and six months post-CV. Thyroid function was evaluated
before and six months after CV.
Analysis of short-term HRV. A 15-min ECG recording
was obtained in all patients under resting conditions before
hospital discharge (4 to 5 h after electrical CV). A second
recording was collected at the time of first control visit (12
to 15 days after CV) if sinus rhythm was present. In both
cases, the ECG signal was acquired on a personal computer
at sampling rate of 1,000 Hz. Off-line analysis was then
performed to compute parameters of short-term HRV. The
principle of the software for data acquisition, QRS detection
and spectral analysis has been previously described (7–10).
After identification of each QRS complex, the program first
calculates the numerical series of RR intervals. Each ta-
chogram was then visually inspected so that irregularities
due to artefacts or premature atrial or ventricular contrac-
tions could be recognized when the cycle interval became
higher or smaller of a user-defined threshold. These irreg-
ularities were linearly interpolated based on the last and first
cycle interval before and after the artefact, respectively, thus
performing a low pass filtering procedure. Some 250 to 300
RR intervals were considered adequate for further analysis
when editing was limited to no more than five events;
otherwise, data were disregarded. As a result, 10 subjects
were excluded from the study and data relative to 93 patients
were considered. The clinical characteristics of the study
population are presented in Table 1.
Autoregressive algorithms were used to provide the num-
ber, center frequency and associated power of the oscillatory
components that characterize spectral analysis of short-term
recording. Adequacy of analysis was verified by formal
statistical criteria such as the Anderson test and the Akaike
criterion. The order of model used to estimate power
spectrum ranged between 9 and 14. As previously reported
(7–10), spectral analysis of short-term recordings is charac-
terized, in addition to a very low frequency component
(VLF, 0 to 0.03 Hz), by two major components at low (LF:
0.03 to 0.15 Hz) and high (HF: 0.15 to 0.40 Hz) frequency.
The LF component has been proposed (7) and utilized,
particularly when expressed in normalized units (n.u.), as an
index of sympathetic modulation, whereas HF, which is a
measure of respiratory sinus arrhythmia, is used as an index
of vagal activity. The ratio between the absolute power of
LF component and HF component was also calculated, and
the LF/HF ratio was used as an index of sympatho-vagal
interaction (7,11,12).
Statistical analysis. Differences between patients with or
without AF recurrence were assessed by the Mann-Whitney
U test for continuous variables, or by the chi-square and
Fisher test exact test when categorical variables were con-
cerned. Baseline predictors of subsequent AF recurrence
were identified by logistic regression analysis. Variables
showing a significant discriminatory effect at univariable
analysis with p # 0.15 were included in the logistic
regression analysis as candidate prognostic factors. This was
the case for the LF/HF ratio. The AF duration, gender and
left atrial diameter failed to achieve the threshold level of
significance but were included in the analysis due to the
prognostic value generally ascribed to them. Pearson’s
goodness-of-fit test was performed to assess the appropri-
ateness of the logistic model.
To appraise the discrimination ability of the LF/HF ratio
for the prediction of AF recurrence, a receiver operating
characteristic (ROC) curve was constructed and the area
under the curve calculated. The optimal cutoff point was
identified as the LF/HR ratio value minimizing the total
number of false results (13).
Statistical analyses were performed using Stata Statistical
Software (Release 6, Stata Corp., College Station, Texas).
Standard deviations and 95% confidence intervals (CI) of
the odd ratios (OR) were used to be reported in the text or
in the tables as measures of variability. All analyses were
two-sided.
Abbreviations and Acronyms
AF 5 atrial fibrillation
CV 5 cardioversion
EGG 5 electrocardiogram/electrocardiographic
HF 5 high frequency component
HRV 5 heart rate variability
LF 5 low frequency component
ROC 5 receiver operating characteristic
Table 1. Clinical Characteristics of the Study Population
(n 5 93)








Duration of AF (months) 12 6 18
Left atrial diameter (mm) 47 6 7
Left ventricular ejection fraction 55 6 11
Previous embolic events 5
Previous electrical cardioversion 21
AF 5 atrial fibrillation.
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RESULTS
As illustrated in Figure 1, 68 patients were in sinus rhythm
12 to 15 days after CV. The clinical characteristics of this
group as well as of patients with AF recurrence are pre-
sented in Table 2. There were no differences in relation to
age, left atrial diameter, underlying heart disease, concom-
itant medical therapy, ejection fraction and duration of
arrhythmia. Using logistic regression analysis, none of the
above parameters was significantly associated with recur-
rence of AF.
The numbers of patients who maintained sinus rhythm
one, three and six months after CV were 61, 60 and 58,
respectively, with a total recurrence rate of 38%. No
thrombo-embolic vascular event was observed.
Data concerning short-term HRV are presented in Table
3. In the entire group, LF component measured in either
absolute or normalized units was relatively predominant
over HF. As a result, the LF/HF ratio, which we used as an
index of sympatho-vagal balance, was 2.36 6 4.34. When
we divided patients in relation to AF recurrence, mean RR
interval and variance were similar in the two groups. In
contrast, patients who relapsed presented a greater LF and
a smaller HF component in comparison to those in sinus
rhythm. This difference was even greater when considering
the LF/HF ratio. Values $2 were observed in 24 patients.
This parameter was significantly associated with AF recur-
rence with an OR of 1.97 (95% CI 1.33 to 2.94). To
evaluate better the predictive value of the LF/HF ratio, an
ROC curve was generated. The area under the ROC curve
was 0.867 (Fig. 2). The LF/HR ratio value minimizing total
number of false results in the prediction of AF recurrence
was 2.2: using this value as the cutoff point, 87% of the
patients would be correctly classified. By using instead a
cutoff value of $2 (Figs. 2 and 3), the LF/HF ratio
presented a 76% sensitivity and a 90% specificity, with a
positive predictive value of 73%, a negative predictive value
of 91% and an overall correct classification rate of 86%. Risk
of AF recurrence was 73% and 9% in patients with LF/HF
ratio values $2 or ,2, respectively, with a risk ratio of 8.
In contrast, no correlation existed between spectral pa-
rameters and, in particular, the LF/HF ratio measured after
CV and AF recurrences occurring beyond two weeks after
restoration of sinus rhythm.
When we considered recordings performed two weeks
after cardioversion in 68 patients still in sinus rhythm (Table
4), there was a tendency of greater values of RR interval,
variance and HF in 10 patients with late AF recurrence,
whereas signs of sympathetic activation and of a reduced
vagal modulation were not detectable in any of the two
groups. Moreover, within the same patient who remained in
sinus rhythm, spectral parameters of short-term HRV
measured a few hours and two weeks after CV did not differ
significantly.
DISCUSSION
This study indicates that an abnormal autonomic modula-
tion may play a major pro-arrhythmic role in the first days
after electrical CV. Signs of enhanced sympathetic and
reduced vagal modulation of sinus node characterized pa-
tients with greater incidence of early recurrence of AF.
Recurrence of AF after CV. Recurrence of AF after
electrical or pharmacological CV is a frequent phenomenon,
which is only partially affected by anti-arrhythmic treatment
(14–18). In a recent Working Group report (1), an average
six-month recurrence rate of 30% to 60% was observed in
chronic or persistent AF. The percent rate was greater when
no anti-arrhythmic drugs were used and smaller when 1c
drugs or amiodarone was administered. In our study, almost
all patients were treated with amiodarone for at least four
weeks before electrical CV and maintained this therapy
throughout the follow-up period. The observed recurrence
rate at six months was 38%: a value in agreement with
previous reports (1,17,18). However, the incidence of recur-
rence was already 27% two weeks after CV and then
increased only slowly in the follow-up period.
A similar time course was recently reported by Tieleman
et al. (2), who analyzed, by transtelephonic monitoring, the
Figure 1. Schematic representation of atrial fibrillation (AF) recurrence
during six-month follow-up period.
Table 2. Clinical Characteristics of Patients With and Without





Number of patients 68 25
Age (yrs) 65 6 10 65 6 8 1.0
Male gender (%) 72 60 0.31
Underlying heart disease (%)
Hypertension 48 52 0.81
Valvular 12 20 0.32
Dilated cardiomyopathy 6 12 0.38
Ischemic 12 4 0.43
None 22 12 0.38
Duration of AF (months) 13.3 6 20 8.4 6 10 0.58
Left atrial diameter (mm) 47 6 7 47 6 8 0.95
Left ventricular ejection
fraction (%)
55 6 11 52 6 13 0.36




AF 5 atrial fibrillation.
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daily incidence of recurrence of persistent AF. These inves-
tigators reported that, of 35 relapses of AF during the first
month after CV, 31 occurred in the first two weeks and 22
in the first five days. At variance with our study, calcium
channel blockers were used in 80% of their patients. Among
the mechanisms responsible for early recurrence, both short
atrial refractory periods (19,20) and loss of rate-dependent
adaptation of refractory period (21–23) have been observed
in patients after electrical CV of chronic AF.
A correlation between higher tendency of AF recurrence
and shortening of monophasic right atrial action potential
was also described (19,20). It is therefore likely that changes
in atrial refractory periods might play a critical role in
causing electrical instability and favoring AF recurrence. In
patients with chronic AF, these electrophysiological
changes were considered to be dependent on a reduction in
the density of ICa in atrial myocites (24). Moreover, it was
also demonstrated that, in presence of adrenergic stimula-
tion, a greater fraction of Ca21 channels unavailable under
basal condition could be recruited, thus contributing to
calcium overload and to AF recurrence (24).
Our data, which indicate that an abnormal autonomic
modulation and, in particular, an increased sympathetic and
a reduced vagal modulation characterize patients with a
higher rate of recurrences, are consistent with the above
findings. The absence, in our study, of measures of atrial-
effective refractory periods and conduction velocities pre-
vents, however, a direct evaluation of the relationship
between the observed changes in HRV and electrical re-
modeling.
The duration of this phase of atrial electrical instability
appears short lived and is followed by a decline in recurrence
rate in our study as well as in the Tieleman et al. study (2).
In the goat model of AF, changes in atrial refractory periods
were no longer evident one week after recovery of sinus
rhythm (3). In patients after electrical CV, recovery of
normal atrial mechanical function was reported to occur
from one to four weeks following restoration of sinus
rhythm (25,26). Thus, the time course of electrical and
mechanical changes seems to parallel the observed changes
in autonomic modulation and to be inversely correlated with
vulnerability for AF recurrence.
As to the possibility that amiodarone might have influ-
enced HRV parameters and recurrence rate, it must be
recalled that this drug, at variance with other anti-
arrhythmic drugs and beta-blockers, is known to have small
effects on short-term HRV parameters during resting con-
Figure 2. Receiver operating characteristic (ROC) curve for LF/HF ratio in prediction of atrial fibrillation recurrence. Point A indicates LF/HF ratio value
equal to 2; point B (LF/HF ratio of 2.2) represents the value that minimizes classification errors. LF/HF 5 low frequency/high frequency.
Table 3. Spectral Parameters of HRV Measured Before Discharge in the Entire Group, in Patients With Early AF Recurrence and





(ms2) LF (ms2) LF (nu) HF (ms2) HF (nu) LF/HF
All patients
(n 5 93)
930 6 159 536 6 655 352 6 495 117 6 222 41 6 24 116 6 316 41 6 21 2.36 6 4.34
AF recurrence
(n 5 25)
924 6 199 505 6 511 326 6 366 201 6 330 62 6 22 49 6 67 22 6 16 5.79 6 6.86
Sinus rhythm
(n 5 68)
932 6 143 548 6 703 358 6 526 86 6 158 33 6 21 140 6 365 48 6 18 1.10 6 1.7
p value 0.567 0.818 0.634 0.007 , 0.0001 0.013 , 0.0001 , 0.0001
AF 5 atrial fibrillation; HF 5 high frequency component; HRV 5 heart rate variability; LF 5 low frequency; VLF 5 very low frequency.
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trolled conditions (27,28), and it was given to all patients
with and without arrhythmia recurrence.
Autonomic modulation and AF. Most of the data con-
cerning the effects of autonomic nervous system and AF are
related to the clinical environment in which this arrhythmia
may occur (6). Vagal mechanisms have been indicated to be
predominant when AF onset occurred after meals or during
nighttime in absence of significant increases in heart rate,
particularly in male patients without evidence of organic
heart disease. In contrast, a pro-arrhythmic role of sympa-
thetic activation was suspected when AF was initiated
during exercise, emotion, or isoproterenol infusion. How-
ever, in most instances, recognition of a specific autonomic
pattern is difficult; also, when HRV analysis was used to
characterize the role of the autonomic nervous system before
AF onset, contrasting results were noticed (29). The com-
plexity of the problem might be partially explained by the
fact that both sympathetic or vagal activation may exert a
pro-arrhythmic action by affecting atrial action potential
duration and conduction velocity (30,31); nonuniform au-
tonomic innervation of the atria may also play a critical
role (32).
In the present study, we observed that a specific HRV
spectral pattern characterized by an LF/HF ratio $2 dis-
tinguished patients prone to early AF recurrence. By using
this cutoff value, we were able to identify correctly the
outcome of 86% of our patients. Moreover, preliminary
results of an ongoing study at our institution show a marked
reduction of incidence of early recurrence (12%) in six
consecutive patients who presented an LF/HF ratio $2 and
received beta-blocker therapy after CV.
The mechanisms causing this autonomic imbalance re-
main, however, to be understood. It is our opinion that the
values of LF/HF ratio $2 observed after CV may indicate
the persistence of an increased sympathetic and a reduced
vagal activity directed to the heart in response to the
mechanical and hemodynamic changes induced by AF. An
abnormal sympatho-vagal balance may contribute directly
and indirectly, through high atrial rate, to intracellular
calcium overload, which is known to be a determinant
component of electrical remodeling process and of vulner-
ability to AF recurrence (33). Alternatively, one may spec-
ulate that the hemodynamic consequences of restoration of
sinus rhythm might have altered autonomic balance in a
subgroup of patients who subsequently became more vul-
nerable to AF recurrence. The absence of a significant
difference in resting heart rate, left atrial diameter, left
ventricular ejection fraction and arrhythmia duration be-
tween patients with and without recurrence makes, in our
opinion, this possibility less likely.
Of interest was the finding that spectral parameters of
HRV recorded about two weeks after CV were substantially
within the normal range and incapable of distinguishing
patients with and without late AF recurrence, an observa-
tion that limits the predictive value of HRV analysis to the
early post-CV period. Moreover, in patients who main-
tained sinus rhythm for six months, no changes occurred in
HRV parameters measured a few hours and two weeks after
CV, thus excluding the possibility that electrical CV, by
itself, could have directly affected HRV.
Spectral parameters of HRV as markers of autonomic
modulation. In the present study, we used spectral analysis
of short-term HRV to obtain information on autonomic
modulation of sinus node (7–12,34). The use of LF/HF
ratio in our logistic regression model was based on the fact
that this parameter may provide a more comprehensive
evaluation of autonomic modulation than individual spectral
components (10). The choice of 2 as the cutoff value for
LF/HF ratio derives from previous evidence in the literature
indicating that values of $2 were consistently associated
Figure 3. Percent (%) recurrence of atrial fibrillation (AF) in relation to the
selected cutoff value of LF/HF ratio. Numbers of patients at risk for
LF/HF ratio $2 and ,2 are shown in the abscissa. LF 5 low frequency;
HF 5 high-frequency component of heart rate variability.
Table 4. Spectral Parameters of HRV Measured Two Weeks After Cardioversion in Patients Who Were in Sinus Rhythm at Time










997 6 181 762 6 1071 390 6 591 138 6 272 36 6 24 121 6 234 39 6 20 1.8 6 2.7
AF recurrence
(n 5 10)
1106 6 193 1286 6 1604 518 6 452 118 6 178 26 6 17 241 6 370 41 6 20 0.9 6 0.8
Sinus rhythm
(n 5 58)
982 6 175 688 6 971 371 6 609 141 6 283 38 6 24 104 6 208 39 6 20 1.9 6 0.4
p value 0.063 0.091 0.085 0.359 0.234 0.062 0.920 0.466
AF 5 atrial fibrillation; HF 5 high frequency component; HRV 5 heart rate variability; LF 5 low frequency; VLF 5 very low frequency.
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with a shift of sympatho-vagal balance toward a sympathetic
activation and a reduced vagal tone (7–12,35). Moreover,
analysis of the discrimination ability of LF/HF ratio using
the ROC approach showed that this value was in close
proximity to the cutoff point, minimizing the total number
of prediction errors.
Conclusions. This study indicates that an abnormal auto-
nomic modulation characterizes patients with a greater
incidence of early AF recurrence after electrical CV despite
anti-arrhythmic treatment. The analysis of short-term HRV
appears, therefore, of clinical value to characterize auto-
nomic tone after CV, to identify patients at higher recur-
rence rate and, if preliminary observations will be
confirmed, to encourage the use of adjunctive beta-blocker
therapy to prevent early AF recurrence.
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